Delcath Systems
DCTH

$9.67

7.46%

Market Cap: $271M

About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Employees: 76

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

533% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 3

100% more capital invested

Capital invested by funds: $40.4M [Q1] → $80.9M (+$40.5M) [Q2]

86% more call options, than puts

Call options by funds: $1.56M | Put options by funds: $839K

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

44% more funds holding

Funds holding: 36 [Q1] → 52 (+16) [Q2]

3.14% more ownership

Funds ownership: 34.61% [Q1] → 37.75% (+3.14%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

86%

upside

Avg. target

$22

124%

upside

High target

$25

159%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Stephens & Co. Sudan Loganathan 33% 1-year accuracy 3 / 9 met price target	159%upside $25	Overweight Reiterated	6 Aug 2024
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target	128%upside $22	Buy Reiterated	6 Aug 2024
Craig-Hallum Chase Knickerbocker 44% 1-year accuracy 8 / 18 met price target	86%upside $18	Buy Initiated	28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about DCTH published over the past 30 days

Zacks Investment Research

Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.

Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The publication, entitled “Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021”, was based on an independent retrospective clini.

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 11:00 a.m. Eastern Time at the Lotte New York Palace Hotel in New York City. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, In.

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by independent investigators in the Annals of Surgical Oncology. The study, titled “Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma,”.

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the European Society for Medical Oncology journal of Gastrointestinal Oncology. The study, titled “Hepatic chemosaturation with melphalan in patients with primary or secondar.

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted on uranium development, oil & gas, and clean energy companies. Healthcare-related stocks are in focus as well, with a couple of biotech picks, a skilled nursing facility operator, and a healthcare technology company included.

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will present data from its FOCUS Phase 3 study at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, which convenes from September 13-17, 2024, in Barcelona, Spain. Poster Presentation Details Title: Subgroup Analysis of FOCUS Phase 3 Trial Efficacy Resu.

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

Delcath's HEPZATO KIT launch is gaining momentum, setting the company up for a strong 2025. My 2025 sales target is about double the consensus. The stock corrected after the Q2 report due to slower-than-expected hospital formulary acceptances, but Delcath is on track to reach 22 active centers in Q1 2025. ICC and mCRC are the next indications that will cement PHP's position as a platform technology. This will increase Delcath stock's multiple.

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted one equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of an individual whose employment commenced in July 2024. The grant totaled the right to purchase an aggregate of 23,000 shares of t.

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript

Delcath Systems Inc (NASDAQ:DCTH ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Swayampakula Ramakanth - H.C. Wainwright Sudan Loganathan - Stephens Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to Delcath Systems' Second Quarter 2024 Earnings Conference Call.

Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript

See News Rankings